Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Masimo Corporation is a medical instruments & supplies business based in the US. Masimo Corporation shares (MASI) are listed on the NASDAQ and all prices are listed in US Dollars. Masimo Corporation employs 2,200 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $135.90 |
|---|---|
| 52-week range | $112.07 - $305.21 |
| 50-day moving average | $131.88 |
| 200-day moving average | $208.64 |
| Wall St. target price | $145.75 |
| PE ratio | 33.7561 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $3.87 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $135.9 from 2022-07-01
| 1 week (2022-06-28) | -0.85% |
|---|---|
| 1 month (2022-06-02) | -4.78% |
| 3 months (2022-04-04) | -9.68% |
| 6 months (2022-01-05) | -48.16% |
| 1 year (2021-07-02) | -46.08% |
|---|---|
| 2 years (2020-07-02) | -41.35% |
| 3 years (2019-07-05) | 149.87 |
| 5 years (2017-07-05) | 48.38% |
Valuing Masimo Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Masimo Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Masimo Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Masimo Corporation shares trade at around 34x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Masimo Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.0004. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Masimo Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Masimo Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $306 million.
The EBITDA is a measure of a Masimo Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.2 billion |
|---|---|
| Operating margin TTM | 21.69% |
| Gross profit TTM | $808.3 million |
| Return on assets TTM | 9.62% |
| Return on equity TTM | 15.31% |
| Profit margin | 17.91% |
| Book value | $28.51 |
| Market capitalisation | $7.3 billion |
TTM: trailing 12 months
We're not expecting Masimo Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Masimo Corporation's shares have ranged in value from as little as $112.07 up to $305.21. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Masimo Corporation's is 0.98. This would suggest that Masimo Corporation's shares are less volatile than average (for this exchange).
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.